This content is machine translated Non-small cell lung cancer with EGRF mutation. New approval for osimertinib for adjuvant therapy Following convincing results from the Phase III ADAURA study, the indication for osimertinib was expanded in Switzerland. Thus, the drug may now also be used for adjuvant therapy in early-stage…
View Post 4 min This content is machine translated Onco-training in St. Gallen Targeted systems therapy in metastatic NSCLC. In more than half of all patients with lung cancer, metastases are already present at the time of diagnosis. In recent years, new compounds have been developed that can be…
